Brainstorm Cell Therapeutics

OverviewSuggest Edit

Brainstorm Cell Therapeutics is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson’s Disease. The Company's platform technology, NurOwn®, uses proprietary culture conditions to induce mesenchymal stem cells to secrete high levels of neurotrophic factors known to promote the survival of neurons. NurOwn® cells dampen the immune system and secrete growth factors that help damaged neurons survive.

TypePublic
Founded2004
HQNew York, US
Websitebrainstorm-cell.com

Latest Updates

Employees (est.) (Dec 2019)32(+4%)
Share Price (Sept 2020)$14.6
Cybersecurity ratingAMore

Key People/Management at Brainstorm Cell Therapeutics

Chaim Lebovits

Chaim Lebovits

Chief Executive Officer
Ralph Kern

Ralph Kern

President and Chief Medical Officer
Arturo Araya

Arturo Araya

Chief Commercial Officer
David Setboun

David Setboun

EVP and Chief Operating Officer
Preetam Shah

Preetam Shah

EVP and Chief Financial Officer
Stacy Lindborg

Stacy Lindborg

EVP and Head of Global Clinical Research
Show more

Brainstorm Cell Therapeutics Office Locations

Brainstorm Cell Therapeutics has offices in New York and Petah Tikva
New York, US (HQ)
1325 6th Ave 28th Floor
Petah Tikva, IL
Basel St 12, Petah Tikva
Show all (2)

Brainstorm Cell Therapeutics Financials and Metrics

Brainstorm Cell Therapeutics Revenue

USD

Net income (Q2, 2020)

(7.4m)

EBIT (Q2, 2020)

(7.4m)

Market capitalization (22-Sept-2020)

460.0m

Closing stock price (22-Sept-2020)

14.6

Cash (30-Jun-2020)

12.2m

EV

449.6m
Brainstorm Cell Therapeutics's current market capitalization is $460 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

General and administrative expense

2.2m1.7m2.1m2.6m3.6m2.8m4.0m5.8m5.8m

R&D expense

1.7m1.8m2.9m4.8m4.9m2.3m977.0k8.3m17.2m

Operating expense total

3.9m3.5m5.0m7.4m8.5m5.1m5.0m14.1m23.0m

EBIT

3.9m(3.4m)(4.9m)(7.4m)(8.5m)(5.1m)(5.0m)(14.1m)(23.0m)
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.9m1.3m3.5m4.3m428.0k547.0k2.5m942.0k536.0k

Accounts Receivable

312.0k24.5m

Prepaid Expenses

69.0k46.0k33.0k32.0k74.0k1.2m1.2m432.0k

Current Assets

2.3m4.9m4.4m9.6m16.8m10.4m9.6m10.3m3.4m
Quarterly
USDQ2, 2011

Financial Leverage

1.6 x
Show all financial metrics

Brainstorm Cell Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

Brainstorm Cell Therapeutics Online and Social Media Presence

Embed Graph

Brainstorm Cell Therapeutics News and Updates

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Corporate and R&D Update

NEW YORK, July 27, 2020 /PRNewswire/ -- BrainStorm-Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, announced today that the Company will hold a conference call to update shareholders...

BrainStorm Cell Therapeutics to Join the Russell 2000® Index and Russell 3000® Index

NEW YORK, June 23, 2020 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NasdaqCM: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that its shares will join the Russell 2000® Index and the broad-market Russell 3000® Index at the...

BrainStorm Cell Therapeutics Raises $10.0 Million in Common Stock Sale at $8.00 Per Share

NEW YORK, March 06, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of cell technologies for neurodegenerative diseases, today announced that it has entered into a definitive agreement with Abbhi Investments, LLC, a healthcare-focused family office b…

Thinking about buying stock in Brainstorm Cell Therapeutics, HP, Plug Power, Virgin Galactic, or Zoom Video Communications?

NEW YORK, Feb. 25, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BCLI, HPQ, PLUG, SPCE, and ZM. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

BrainStorm Cell Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Provide a Corporate Update

NEW YORK, Feb. 10, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, today announced that the Company will hold a conference call to update shareholders on financial results for the fourth qua…

BrainStorm Cell Therapeutics to Present at the 2020 Biotech Showcase and 3rd Annual Neuroscience Innovation Forum at JPM Week

NEW YORK, Jan. 07, 2020 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President and Chief Executive Officer, will provide a corporate overview at the 202…
Show more

Brainstorm Cell Therapeutics Blogs

David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer

David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer Content Import Wed, 04/01/2020 - 09:01 David Setboun Joins BrainStorm as Executive Vice President and Chief Operating Officer 04/01/2020 This release is a backfill from a News Wire …

BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19

BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19 Content Import Mon, 03/16/2020 - 03:00 BrainStorm to Hold a Conference Call to Update Investors on Corporate Steps Taken to Address COVID-19 03/16/2020 This release i…

Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial

Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial Content Import Thu, 02/27/2020 - 01:00 Fifth and Final Site Announced for BrainStorm’s Progressive Multiple Sclerosis Phase 2 Clinical Trial 02/27/2020 This release i…

BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS

BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS Content Import Tue, 02/11/2020 - 06:00 BrainStorm Cell Therapeutics and FDA Agree to Potential NurOwn® Regulatory Pathway for Approval in ALS 02/11/2020 This release…

BrainStorm Cell Therapeutics to make scientific presentations at the 30th International Symposium on ALS/MND

BrainStorm’s Chief Operating and Chief Medical Officer, Ralph Kern MD MHSc, will make a podium presentation at Clinical Trials Session NEW YORK , Nov. 26, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in the development of innovative autologous cellular

BrainStorm Announces the Mount Sinai Medical Center as a Progressive MS Phase 2 Clinical Trial Site

NEW YORK , Nov. 25, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. ( NASDAQ: BCLI ), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases, today announced that The Mount Sinai Medical Center, internationally acclaimed for its
Show more

Brainstorm Cell Therapeutics Frequently Asked Questions

  • When was Brainstorm Cell Therapeutics founded?

    Brainstorm Cell Therapeutics was founded in 2004.

  • Who are Brainstorm Cell Therapeutics key executives?

    Brainstorm Cell Therapeutics's key executives are Chaim Lebovits, Ralph Kern and Arturo Araya.

  • How many employees does Brainstorm Cell Therapeutics have?

    Brainstorm Cell Therapeutics has 32 employees.

  • Who are Brainstorm Cell Therapeutics competitors?

    Competitors of Brainstorm Cell Therapeutics include InVivo Therapeutics, Vaccitech and NorthSea Therapeutics.

  • Where is Brainstorm Cell Therapeutics headquarters?

    Brainstorm Cell Therapeutics headquarters is located at 1325 6th Ave 28th Floor, New York.

  • Where are Brainstorm Cell Therapeutics offices?

    Brainstorm Cell Therapeutics has offices in New York and Petah Tikva.

  • How many offices does Brainstorm Cell Therapeutics have?

    Brainstorm Cell Therapeutics has 2 offices.